Buy GLP-2 T (Tirzepatide) Online — GLP Weight-Loss Peptide
Dual GIP/GLP-1 Agonist — Superior Weight Loss
Last updated May 2026 · COA-verified
Verified GLP-2 T (Tirzepatide) — Tirzepatide (GLP-2 T) is a dual GIP/GLP-1 receptor agonist showing up to 22.5% body weight reduction in trials — outperforming semaglutide in head-to-head data.
- Up to 22.5% body weight reduction — superior to semaglutide in head-to-head trials
- Dual GIP + GLP-1 receptor activation — two complementary appetite and metabolism mechanisms
- SURPASS-2: outperformed semaglutide at all doses tested
- Improved HbA1c reduction for metabolic health
- Reduces visceral fat more effectively than single-mechanism agents
COA verified · US domestic shipping
Scaling Tirzepatide From 2.5 mg to 15 mg
Escalation Protocol:
• Week 1-4: 2.5mg subcutaneous weekly
• Week 5-8: 5mg subcutaneous weekly
• Week 9-12: 7.5mg subcutaneous weekly
• Week 13-16: 10mg subcutaneous weekly
• Week 17+: 12.5-15mg (maximum dose, as tolerated)
Injection: Once weekly subcutaneous. Rotate sites.
Tirzepatide (GLP-2 T): The Dual Agonist That Outperformed Semaglutide in Every Trial
22.5% Weight Reduction
SURMOUNT-1: maximum dose achieved 22.5% body weight reduction — the highest efficacy ever demonstrated in controlled weight loss trials at the time of publication.
Beat Semaglutide
SURPASS-2 head-to-head: tirzepatide outperformed semaglutide at all three doses tested — superior HbA1c and weight loss in direct comparison.
Dual Mechanism
GIP + GLP-1 dual agonism creates synergistic metabolic effects that neither receptor can achieve alone — explaining the superior clinical outcomes.
Visceral Fat Priority
Tirzepatide has shown preferential reduction of visceral adipose tissue — the metabolically dangerous fat that surrounds organs and drives inflammation.
Tirzepatide vs Semaglutide — Head-to-Head Data
Select a clinical metric to compare outcomes from published trial data.
SURPASS-2 head-to-head: tirzepatide outperformed semaglutide at all three doses (5mg, 10mg, 15mg).
Why tirzepatide outperforms: Dual GIP + GLP-1 receptor agonism produces synergistic effects that neither receptor can achieve alone. GIP receptor activation directly impacts adipose tissue and potentiates insulin secretion through a different mechanism than GLP-1, explaining the superior clinical outcomes.
Data sourced from STEP, SUSTAIN, SURPASS, and SURMOUNT clinical trial programs. For educational purposes.
Where Tirzepatide Pulls Ahead of Semaglutide
- Up to 22.5% body weight reduction — superior to semaglutide in head-to-head trials
- Dual GIP + GLP-1 receptor activation — two complementary appetite and metabolism mechanisms
- SURPASS-2: outperformed semaglutide at all doses tested
- Improved HbA1c reduction for metabolic health
- Reduces visceral fat more effectively than single-mechanism agents
- Glucose-dependent insulin secretion — minimal hypoglycemia risk
- Beneficial effects on lipid profiles and cardiovascular markers
- Superior weight loss without proportional increase in side effects
Why GIP + GLP-1 Beats GLP-1 Alone
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both receptor types simultaneously, it achieves superior weight loss efficacy compared to GLP-1 agonists alone. Available commercially as Mounjaro (diabetes) and Zepbound (obesity).
▸Why Dual Agonism Is More Effective
GIP receptors and GLP-1 receptors have complementary but distinct mechanisms:
▸GIP (GIP receptor):
→Potentiates insulin secretion synergistically with GLP-1
→Reduces glucagon secretion
→Acts on adipose tissue to regulate fat storage
→Potential direct CNS appetite suppression
▸GLP-1 (GLP-1 receptor):
→Slows gastric emptying
→Reduces appetite via hypothalamic action
→Glucose-dependent insulin stimulation
Together, these mechanisms produce synergistic weight loss that exceeds GLP-1 agonism alone.
▸Clinical Superiority
SURMOUNT trials: Up to 22.5% body weight reduction at highest dose (15mg) over 72 weeks — significantly greater than semaglutide's ~15-16% in comparable populations.
In the SURPASS-2 trial directly comparing tirzepatide vs semaglutide, tirzepatide achieved superior weight loss at all doses tested.
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available for all products.
GLP-2 T (Tirzepatide)
COA verified · Third-party tested · US domestic shipping
Buy Now View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Tirzepatide Without the Marketing Spin
How does tirzepatide compare to semaglutide for weight loss?+
Tirzepatide consistently outperforms semaglutide in head-to-head comparisons. The SURMOUNT trials showed up to 22.5% body weight reduction with tirzepatide 15mg vs. 14.9% with semaglutide. Tirzepatide's dual GIP/GLP-1 agonism provides both superior fat loss and better muscle preservation than GLP-1 agonism alone.
What makes tirzepatide different from semaglutide?+
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP receptor agonism adds adipose-tissue remodeling and improved insulin sensitivity to the appetite suppression of GLP-1. This combination produces greater fat loss with less lean muscle loss than semaglutide monotherapy.
Complementary Peptides to Tirzepatide
Anti-AgingNAD+ 500mg
Cellular Energy & Longevity Cofactor
Verified NAD+ 500mg — NAD+ is the master cellular energy molecule that declines 50% by age 50 — supplementation restores sirtuin activity, DNA repair, and mitochondrial function.
Weight LossGLP-1 S (Semaglutide)
Next-Gen GLP-1 Receptor Agonist for Weight Loss
Trusted GLP-1 S (Semaglutide) — Semaglutide (GLP-1 S) is a GLP-1 receptor agonist with clinical trials showing 15-20% body weight reduction — the most effective pharmacological weight loss agent studied.
Weight LossGLP-3 R (Retatrutide)
Triple Receptor Agonist — Next-Level Weight Loss
Buy GLP-3 R (Retatrutide) — Retatrutide (GLP-3 R) is a triple GLP-1/GIP/glucagon receptor agonist showing 24% body weight reduction in Phase II — the most potent weight loss peptide in clinical development.